{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:33Z","timestamp":1786649913591,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Antiphospholipid antibody syndrome (APAS) is regarded as the most frequently acquired risk factor for thrombophilia. The obstetric manifestations of APAS include early or late pregnancy losses and complications like preeclampsia and fetal growth restriction. Its timely diagnosis and treatment can improve maternal and neonatal outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To study the pregnancy outcome of patients with APAS treated with heparin and aspirin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design:<\/jats:title>\n                    <jats:p>This was a retrospective study of pregnancy outcome in 42 consecutive women with APAS, treated with heparin and aspirin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The case records of 42 diagnosed cases of APAS with pregnancy, over a 3-year period, were studied. The pregnancy outcome in this group was compared before and after treatment with heparin and low-dose aspirin in terms of abortions, intrauterine deaths and live birth rate. The outcome of the present pregnancy in terms of fetal and maternal complications was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mean age and average parity of women with APAS were 30.1\u00b14.1 years and 3.2\u00b11.2, respectively. Among the treated patients of APAS, 13 (30.9%) had preeclampsia and 9 (21.4%) had intrauterine growth restriction (IUGR). There were 2 (4.7%) intrauterine deaths, 4 (9.5%) missed abortions and 3 (7.1%) abruptio placentae. Women with APAS had a live birth rate of 4.6% before treatment and 85.7% in the index pregnancy after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Treatment of pregnant women with APAS results in marked improvement in the live birth rate (4.6-85.7%). However, complications like preeclampsia and IUGR occur even after treatment, requiring strict monitoring and timely delivery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.74285","type":"journal-article","created":{"date-parts":[[2011,1,5]],"date-time":"2011-01-05T01:58:23Z","timestamp":1294192703000},"page":"16-19","source":"Crossref","is-referenced-by-count":13,"title":["The obstetric outcome following treatment in a cohort of patients with antiphospholipid antibody syndrome in a tertiary care center"],"prefix":"10.4103","volume":"57","author":[{"given":"V","family":"Dadhwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AK","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Deka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240205","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N Engl J Med"},{"key":"R2-5-20240205","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R4-5-20240205","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00002281-200205000-00007","article-title":"Treatment of the antiphospholipid syndrome","volume":"14","author":"Roubey","year":"2002","journal-title":"Curr Opin Rheumatol"},{"key":"R5-5-20240205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jri.2005.01.006","article-title":"Heparin treatment in pregnancy loss: Potential therapeutic benefits beyond anticoagulation","volume":"66","author":"Girardi","year":"2005","journal-title":"J Reprod Immunol"},{"key":"R6-5-20240205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jri.2006.12.003","article-title":"The obstetric antiphospholipid syndrome","volume":"77","author":"Derksen","year":"2008","journal-title":"J Reprod Immunol"},{"key":"R7-5-20240205","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3899\/jrheum.080763","article-title":"Low molecular weight heparin and aspirin for recurrent pregnancy loss: Results from the randomized, controlled HepASA Trial","volume":"36","author":"Laskin","year":"2009","journal-title":"J Rheumatol"},{"key":"R8-5-20240205","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R9-5-20240205","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.thromres.2008.03.012","article-title":"Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy","volume":"123","author":"Ruffatti","year":"2009","journal-title":"Thromb Res"},{"key":"R10-5-20240205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2393-9-11","article-title":"Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: Analysis of a population-based hospital dataset","volume":"9","author":"Nodler","year":"2009","journal-title":"BMC Pregnancy Childbirth"},{"key":"R11-5-20240205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejogrb.2003.09.040","article-title":"Antiphospholipid syndrome and second or third trimester fetal death: Follow -up in the next pregnancy","volume":"114","author":"Bats","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R12-5-20240205","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1471-0528.2002.00077.x","article-title":"Placental massive perivillous fibrin deposition associated with antiphospholipid antibody syndrome","volume":"109","author":"Sebire","year":"2002","journal-title":"Br J Obstet Gynaecol"},{"key":"R13-5-20240205","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0002-9378(92)91596-3","article-title":"Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin","volume":"166","author":"Cowchock","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"R14-5-20240205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0002-9378(89)90468-7","article-title":"Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody","volume":"160","author":"Lockshin","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"R15-5-20240205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1471-0528.2006.01201.x","article-title":"Use of intravenous immunoglobulin for treatment of recurrent miscarriage: A systematic review","volume":"114","author":"Hutton","year":"2007","journal-title":"Br J Obstet Gynaecol"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201157010-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:51Z","timestamp":1786647591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201157010-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.74285","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]}}}